EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Myxedema coma in COVID-19

Takashi Yuichi, Kawanami Daiji

Annals of Clinical Endocrinology and Metabolism · 2021

DOI: 10.29328/journal.acem.1001021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Endocrinology and Metabolism, 2021. Verfasst von Takashi Yuichi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 infection is associated with thyroid disorders. It has been reported that myxedema coma (MC) can be complicated with COVID-19. COVID-19-related thyroid disorders consist of a broad spectrum of thyroid dysfunction, from thyrotoxicosis to decompensated hypothyroidism. It is possible that both primary and central thyroid disorders are induced by COVID-19 due to systemic inflammatory and immune responses. We experienced two cases in which patients with COVID-19 developed MC with central hypothyroidism. It is likely that MC affected the severity of COVID-19. It is necessary to consider the existence of MC during SARS-CoV-2 infection. We propose the potential mechanisms.

Zitieren

APA

Yuichi, T., & Daiji, K. (2021). Myxedema coma in COVID-19. Annals of Clinical Endocrinology and Metabolism. https://doi.org/10.29328/journal.acem.1001021

Vancouver

Yuichi T, Daiji K. Myxedema coma in COVID-19. Annals of Clinical Endocrinology and Metabolism. 2021. doi:10.29328/journal.acem.1001021

BibTeX
@article{Yuichi2021,
  author = {Yuichi, Takashi and Daiji, Kawanami},
  title = {Myxedema coma in COVID-19},
  journal = {Annals of Clinical Endocrinology and Metabolism},
  year = {2021},
  doi = {10.29328/journal.acem.1001021}
}
Kostenlos starten →